CETIRIZINE HYDROCHLORIDE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Cetirizine Hydrochloride Market Size and Share Analysis -2026 To 2033

The Cetirizine Hydrochloride Market size is anticipated to grow at a CAGR of 7.2% with USD 2.4 Bn in 2026 and is expected to reach USD 3.9 Bn in 2033. The primary drivers are largely defined by the rising prevalence of allergic disorders, including allergic rhinitis, conjunctivitis, and eczema, across all age groups. Some of the other contributing factors include growing over-the-counter availability, increased awareness of non-sedating antihistamines, expanded pediatric formulations, and the adoption of oral solutions and syrups for ease of use. According to the World Allergy Organization, over 400 million people globally suffered from allergic rhinitis, with a notable increase in urban populations experiencing seasonal as well as perennial allergies.

Key Takeaways

• The tablets segment is likely to dominate the market with 68.5% in 2026. The segment’s growth is owing to the extensive global preference for oral solid dosage forms due to ease of administration, accurate dosing, longer shelf life, and patient compliance in treating allergic conditions.
• The adults segment is set to lead with 65.00% in 2026. The segment’s growth is owing to the rising prevalence of allergic disorders like allergic rhinitis, urticaria, and other hypersensitivity conditions among the adult population. This is driven by the environmental pollution, lifestyle changes, and seasonal allergy patterns. Approximately one‑quarter of the U.S. adults (25.2%) report having a seasonal allergy, thereby highlighting the broad consumer base for antihistamines like cetirizine.
• The allergic rhinitis segment is set to lead with 61.5% in 2026. The segment’s growth is owing to the increasing incidence of allergic rhinitis globally, which is boosted by urbanization, a higher exposure to allergens, and the growing awareness around early diagnosis and treatment.
• The retail pharmacies segment is set to lead with 57.2% in 2026. The segment’s growth is owing to the wider network coverage of retail and community pharmacies, easy access to OTC cetirizine formulations, and extensive promotional activities by pharmaceutical distributors. Additionally, an estimated 62.7 million packages of OTC cetirizine and levocetirizine products were purchased by consumers from U.S. retail outlets through point.
• North America is expected to acquire the prominent share of 36.20% in 2026. The region’s growth is owing to the well‑established healthcare infrastructure, high prevalence of allergic diseases, strong consumer purchasing power, and supportive regulatory frameworks that enhance access to antihistamine therapies. CDC data confirms that allergic rhinitis (commonly known as hay fever) is highly prevalent, affecting approximately 1 in 4 to 1 in 3 adults across North America, further underpinning market demand.

Rising Prevalence of Allergic Conditions and Self ‑Medication Trends is Transforming the Cetirizine Hydrochloride Market in the US

The cetirizine hydrochloride market in the United States is expanding due to the high prevalence of allergic conditions. According to the 2024 National Health Interview Survey, nearly 31.7% of adults reported at least one diagnosed allergic condition (seasonal allergy, eczema, or food allergy) in 2024, with 25.2% specifically experiencing seasonal allergies. This prevalence sustains the demand for cetirizine products, commonly used for relief of seasonal allergic rhinitis as well as chronic urticaria.

In regulatory updates, the U.S. Food and Drug Administration (FDA) issued a drug safety communication in May 2025 requiring revised labeling for cetirizine and levocetirizine to warn about rare but severe pruritus upon abrupt discontinuation after long

In November 2025, Marksans Pharma’s UK subsidiary, Relonchem Limited, received MHRA approval for its anti-allergy medicine, Cetirizine Dihydrochloride 1 mg/ml oral solution. The approval enables marketing in the UK, expanding the company’s allergy treatment portfolio.

Shift to Advanced and Patient ‑Friendly Formulations: A Major Breakthrough in the Cetirizine Hydrochloride Market

The Cetirizine Hydrochloride Market is shifting toward patient-friendly formats such as oral solutions, capsules, and orally disintegrating tablets, as allergy therapy is increasingly used in daily home-care settings. CDC/NCHS reported that 25.7% of U.S. adults had seasonal allergy in 2021, while 18.9% of children had seasonal allergy, thereby supporting the demand for flexible pediatric and adult formulations.

In March 2026, Preferred Pharmaceuticals Inc. received FDA approval for Cetirizine Hydrochloride Oral Solution USP, 5 mg/5 mL (1 mg/mL) in the U.S. This marks it as an approved human prescription drug. It was revised on DailyMed, listing 5 mg/5 mL strength, sugar-free and dye-free grape-flavored syrup, enclosed dosing cup, and use for children aged 2 years and above, thereby improving pediatric dosing convenience.

Current Events and Their Impact on the Cetirizine Hydrochloride Market

Segmental Insights 

Why is Tablets Acquiring the Largest Share?

On the basis of dosage form, the tablets segment is projected to account for the largest Cetirizine Hydrochloride Market share of 68.5% in 2026. The segment’s growth is owing to the sustained preference for once‑daily 10 mg tablet formulations in allergic rhinitis treatment and broad over‑the‑counter availability backed by regulatory approvals.

In children, 20.6% had a diagnosed seasonal allergy in 2024, underscoring pediatric use of tablet formulations. In addition, allergic rhinitis affects between 10% and 40% of the global population annually, thereby underscoring the broad target patient base for tablet antihistamines.

In October 2024, Indoco Remedies Limited received the final USFDA approval for its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets USP, 10 mg (OTC). The approval enables Indoco to market a generic equivalent of Zyrtec Allergy Tablets, 10 mg of Johnson & Johnson Consumer Inc. This is enhancing access to affordable allergy relief options in key global markets.

Allergic Rhinitis hold the Largest Market Share 

On the basis of application, the allergic rhinitis segment lead with a major 61.5% share in 2026. The segment’s growth is owing to the to the high prevalence of allergic conditions and the widespread preference for second‑generation antihistamine drugs like cetirizine.

According to the U.S. CDC National Ambulatory Medical Care Survey, approximately 4.1 million physician office visits in 2025 were attributed primarily to allergic rhinitis, reflecting the high clinical engagement and frequent recommendation of cetirizine tablets.

In addition, allergic rhinitis affects an estimated 15% of the U.S. population which is about 50 million individuals. This underscores its large patient base as well as a substantial demand for antihistamine therapies globally.

Cetirizine Hydrochloride Market Trends

• The rising prevalence of allergic conditions like allergic rhinitis, urticaria, and hay fever substantially propels the demand for antihistamines like cetirizine hydrochloride globally.
• Cetirizine remains a preferred second‑generation antihistamine owing to its effective symptom relief with minimal sedation and wide availability in tablets, syrups, and chewable forms, thereby supporting the adherence across age groups.
• The OTC availability and broad retail pharmacy distribution facilitate consumer access, with tens of millions of packages sold annually, thereby reinforcing self‑care treatment trends.
• The increasing healthcare awareness, telehealth assessments, and generic product expansion improve treatment reach, bolstering market expansion in both developed as well as emerging regions.
• The innovations in product formulations like oral solutions, fast‑dissolving tablets, and pediatric syrups are emerging to improve convenience and compliance among diverse patient populations.
• The widespread availability and cost‑competitiveness of generic cetirizine products further enhance market accessibility, particularly in price‑sensitive regions.
• The increasing integration of digital health tools and telemedicine for allergy management is helping consumers access timely advice, diagnosis, and prescription refills, thereby strengthening the broader treatment reach.

Regional Insights 

North America Dominates Owing to the High Allergic Condition Prevalence and Expanding OTC Access

The North America region accounts for 36.2% of the market share in 2026. The region’s growth is owing to by the increasing prevalence of allergic conditions, such as seasonal and perennial allergic rhinitis, combined with strong OTC accessibility of second‑generation antihistamines. In addition, heightened awareness and adoption of convenient dosage forms, including chewables and gummies, are fueling market expansion.

A Phase 1 clinical study evaluating the bioavailability of a 10 mg cetirizine HCl gummy formulation is registered with ClinicalTrials.gov, with an estimated completion in September 2025, indicating ongoing formulation development efforts. Additionally, regulatory records show a new OTC chewable cetirizine hydrochloride label was approved effective April 2026 in the FDA database, reflecting evolving product approvals within the segment.

In February 2024, Harrow, Inc. entered an exclusive licensing agreement with Apotex Inc. to market and distribute several ophthalmic products in Canada, including pursuing approval for ZERVIATE (cetirizine ophthalmic solution 0.24%).

Asia Pacific Cetirizine Hydrochloride Market Trends

Asia Pacific is expected to witness strong growth in Cetirizine Hydrochloride Market over the forecast period. The region’s growth is owing to the increasing prevalence of allergic disorders such as allergic rhinitis and conjunctivitis, alongside rising consumer awareness of over-the-counter antihistamine options supported by government health initiatives.

In India, the National Pharmaceutical Pricing Authority (NPPA) computed and capped the retail price of cetirizine hydrochloride ophthalmic solution (0.24% w/v) at Rs 14.42 per ml for 5 ml packs in early 2026 under its Drug Price Control Order framework, highlighting active government pricing oversight and affordability controls in key formulations.

On the clinical trial front, an ongoing randomized study (NCT07236372) is investigating higher cetirizine dosing for symptom relief in allergic conditions, indicating continued research into optimized use.

In December 2024, Nicox SA announced the first commercial sale of ZERVIATE (cetirizine ophthalmic solution) 0.24% in China through its exclusive partner, Ocumension Therapeutics. The product was approved in China in September 2024 and is indicated for ocular itching associated with allergic conjunctivitis.

Increasing Allergy Prevalence and Expanded Generic Availability is Accelerating the Cetirizine Hydrochloride Market in United States

The Cetirizine Hydrochloride Market in the United States is experiencing substantial growth. The growth is owing to increasing allergy prevalence and expanded generic availability.

According to the U.S. Food and Drug Administration data, an estimated 26.8 million prescriptions for cetirizine and levocetirizine were dispensed from U.S. outpatient pharmacies in 2022, with 65% linked to OTC use, thereby reflecting the sustained high utilization.

In February 2026, Aurohealth LLC received the FDA approval for Cetirizine Hydrochloride as an over-the-counter (OTC) human drug in the U.S. This marks it as an officially approved human OTC medication.

China Cetirizine Hydrochloride Market Trends

The Cetirizine Hydrochloride Market in China is experiencing substantial growth. The growth is owing to the increasing prevalence of allergic conditions like allergic rhinitis. The epidemiological studies show that it affects an estimated 18% of the Chinese population and has risen substantially over recent decades.

The regulatory developments continue to propel the market expansion. In August 2025, the National Medical Products Administration (NMPA) granted a quality and efficacy consistency evaluation approval for the 10 mg cetirizine hydrochloride tablets manufactured by Xinhua Pharmaceutical. This made it the first OTC cetirizine product in China to achieve this regulatory milestone, thereby enhancing generic confidence and competitive positioning.

Who are the Major Companies in Cetirizine Hydrochloride Industry

Some of the major key players in Cetirizine Hydrochloride are Johnson and Johnson, Mylan, Inc., Nicox S.A., Strides Shasun, Apotex, Inc., Teva UK Limited, Aurobindo Pharma Limited, Jubilant Life Sciences, Tris Pharma, Inc., and Cipla Ltd.

Key News

• In January 2026, ESTEVE acquired TerSera Therapeutics LLC’s Infusion Specialty Therapies (IST) Business Unit, expanding ESTEVE’s presence in the U.S. market. The IST portfolio includes two specialty products: Prialt (ziconotide intrathecal infusion) for severe chronic pain management, and Quzyttir® (cetirizine hydrochloride injection), strengthening ESTEVE’s specialty therapy offerings.
• In December 2025, the FDA approved a supplemental NDA (sNDA 022155/S-29) for Kenvue Brands LLC’s Zyrtec Allergy (cetirizine hydrochloride) oral solution, 1 mg/mL, introducing a new flavor, “Cooling Tropical Breeze,” for 4 fl oz and 8 fl oz bottles.

Market Report Scope 

Analyst Opinion

• The Cetirizine Hydrochloride market is driven by the persistent prevalence of allergic conditions. Globally, allergic rhinitis affects over 400 million people, and the prevalence is increasing due to urbanization, pollution, and changing lifestyles. This demonstrates that the market growth is fueled by medical necessity rather than transient trends.
• Cetirizine is among the one of the most prescribed second-generation antihistamines. The estimates suggest that more than 250 million prescriptions are filled annually worldwide, thereby highlighting its strong acceptance among healthcare providers and patients alike.
• The recent product innovations like new oral solution flavors and combination therapies with decongestants are gaining traction. The clinical data indicate that cetirizine provides effective symptom relief for more than 80% of patients with allergic rhinitis and urticaria, with minimal sedation. This high efficacy and safety profile is expected to encourage broader adoption, supporting market expansion across both developed and emerging regions.

Market Segmentation

• By Dosage Form (Revenue, USD Bn, 2021-2033)
  • Tablet
  • Syrup
  • Solution
• By Age Group (Revenue, USD Bn, 2021-2033)
  • Adult
  • Pediatric
• By Application (Revenue, USD Bn, 2021-2033)
  • Allergic Rhinitis
  • Allergic Conjunctivitis
  • Eczema
  • Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Pharmaceutical Manufacturers (Generic & Branded)
• Active Pharmaceutical Ingredient (API) Producers
• Contract Manufacturing Organizations (CMOs)
• Clinical Research Organizations (CROs)
• Hospital Pharmacists & Procurement Officers
• Regulatory Affairs Consultants
• Drug Distribution & Supply Chain Experts
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• IQVIA
• Others

Magazines

• Pharmaceutical Executive
• PharmaTimes
• Chemical & Engineering News
• The Pharma Letter
• Elsevier Pharma News
• Others

Journals

• Journal of Pharmaceutical Sciences
• International Journal of Pharmaceutics
• European Journal of Clinical Pharmacology
• Drug Development and Industrial Pharmacy
• Therapeutic Advances in Drug Safety
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters
• Bloomberg News
• The Economic Times (India)
• Others

Associations

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
• U.S. Food & Drug Administration (FDA) – Division of Allergy, Immunology, and Transplant Products
• European Medicines Agency (EMA)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• Indian Pharmaceutical Alliance (IPA)
• Others

Public Domain Sources

• U.S. FDA – Drug Approvals & Databases
• European Medicines Agency – Public Assessment Reports
• WHO – Essential Medicines & Drug Statistics
• National Center for Biotechnology Information (NCBI)
• ClinicalTrials.gov
• Indian Ministry of Health & Family Welfare – CDSCO
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years